{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:33Z","timestamp":1792693293994,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.02.023","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:38:00Z","timestamp":1774021080000},"page":"1296-1307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease"],"prefix":"10.1016","volume":"109","author":[{"given":"David Z.I.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bonefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Crater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie F.","family":"Furberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Palardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dre Lysane","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medea","family":"Amashukeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lela","family":"Beglarashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irakli","family":"Mukhashavri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Okropiridze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokosha","family":"Pachulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eka","family":"Skhiladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mamasakhlisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zviad","family":"Svanadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.02.023_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.kint.2026.02.023_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: an update","author":"Kazancio\u011flu","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2026.02.023_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jama.2024.24671","article-title":"Diabetes and chronic kidney disease","volume":"333","author":"Limonte","year":"2025","journal-title":"JAMA"},{"issue":"5S","key":"10.1016\/j.kint.2026.02.023_bib4","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.023_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib7","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2015.63","article-title":"Cannabinoid receptor 1 is a major mediator of renal fibrosis","volume":"88","author":"Lecru","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.023_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.720734","article-title":"Cannabinoid receptor 1 inhibition in chronic kidney disease: a new therapeutic toolbox","volume":"12","author":"Dao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.kint.2026.02.023_bib13","doi-asserted-by":"crossref","first-page":"E5420","DOI":"10.1073\/pnas.1419901111","article-title":"Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy","volume":"111","author":"Jourdan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2026.02.023_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.ki.5002540","article-title":"Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats","volume":"72","author":"Janiak","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.023_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1138416","article-title":"Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy","volume":"3","author":"Jacquot","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kint.2026.02.023_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.15353","article-title":"Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome: a randomized, placebo-controlled, double-blind phase 1b study","volume":"26","author":"Crater","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.02.023_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-8587(25)00216-5","article-title":"Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Knop","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2026.02.023_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ekir.2017.01.010","article-title":"Bariatric surgery and kidney-related outcomes","volume":"2","author":"Chang","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.023_bib19","unstructured":"European Medicines Agency (EMA). Guideline for good clinical practice E6(R2), Step 5. 2016. Accessed August 21, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5-revision-2_en.pdf"},{"key":"10.1016\/j.kint.2026.02.023_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.02.023_bib23","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.02.023_bib29","unstructured":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN). ClinicalTrials.gov Identifier: NCT01874431. Updated July 1, 2021. Accessed April 18, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01874431"},{"key":"10.1016\/j.kint.2026.02.023_bib24","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.023_bib30","unstructured":"Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria. ClinicalTrials.gov Identifier: NCT00097955. Updated May 17, 2017. Accessed April 8, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00097955"},{"key":"10.1016\/j.kint.2026.02.023_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.02.023_bib31","unstructured":"The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors (VITAL). ClinicalTrials.gov Identifier: NCT00421733. Updated January 20, 2012. Accessed April 8, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00421733"},{"key":"10.1016\/j.kint.2026.02.023_bib26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.kint.2026.02.023_bib27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ijo.2010.38","article-title":"A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study","volume":"34","author":"Proietto","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.kint.2026.02.023_bib28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/oby.2010.352","article-title":"Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance","volume":"19","author":"Aronne","year":"2011","journal-title":"Obesity (Silver Spring)"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:52:21Z","timestamp":1779270741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0085253826002176"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}